<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Clinical features, diagnosis, and staging of gastric cancer
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Clinical features, diagnosis, and staging of gastric cancer
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Clinical features, diagnosis, and staging of gastric cancer
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul F Mansfield, MD, FACS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kenneth K Tanabe, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jonathan B Kruskal, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sonali M Shah, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Shilpa Grover, MD, MPH, AGAF
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 21, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with gastric cancer in the United States are symptomatic and already have advanced, incurable disease at the time of presentation. Despite advances in medicine, approximately 50 percent have disease that extends beyond locoregional confines at the time of presentation, and only one-half of those who appear to have locoregional tumor involvement can undergo potentially curative resection. Surgically curable early gastric cancers are usually asymptomatic and are only infrequently detected outside of screening programs. Screening is not widely performed, except in countries that have a very high incidence, such as Japan, Korea, Venezuela, and Chile. (See
         <a class="medical medical_review" href="/z/d/html/2618.html" rel="external">
          "Gastric cancer screening"
         </a>
         .)
        </p>
        <p>
         The common presenting symptoms of and diagnostic approaches to gastric cancer will be reviewed here. Epidemiology, issues related to screening for high-risk patients, and treatment of gastric cancer are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2616.html" rel="external">
          "Epidemiology of gastric cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2618.html" rel="external">
          "Gastric cancer screening"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2523.html" rel="external">
          "Adjuvant and neoadjuvant treatment of gastric cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2481.html" rel="external">
          "Surgical management of invasive gastric cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2473.html" rel="external">
          "Initial systemic therapy for locally advanced unresectable and metastatic esophageal and gastric cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          CLINICAL FEATURES
         </span>
        </p>
        <p class="headingAnchor" id="H45647872">
         <span class="h2">
          Signs and symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with gastric cancer are symptomatic. Weight loss and persistent abdominal pain are the most common symptoms at initial diagnosis  (
         <a class="graphic graphic_table graphicRef67702" href="/z/d/graphic/67702.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]. Approximately 25 percent of patients with gastric cancer have a history of gastric ulcer. (See
         <a class="medical medical_review" href="/z/d/html/26.html" rel="external">
          "Peptic ulcer disease: Clinical manifestations and diagnosis", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Weight loss usually results from insufficient caloric intake, rather than increased catabolism, and may be attributable to anorexia, nausea, abdominal pain, early satiety, and/or dysphagia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         When present, abdominal pain tends to be epigastric, vague, and mild early in the disease but more severe and constant as the disease progresses.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dysphagia is a common presenting symptom in patients with cancers arising in the proximal stomach  (
         <a class="graphic graphic_figure graphicRef79793" href="/z/d/graphic/79793.html" rel="external">
          figure 1
         </a>
         ) or at the esophagogastric junction (EGJ). A pseudoachalasia syndrome may occur as the result of involvement of Auerbach's plexus due to local extension or to malignant obstruction near the gastroesophageal junction [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2268.html" rel="external">
          "Achalasia: Pathogenesis, clinical manifestations, and diagnosis", section on 'Differential diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nausea or early satiety may result from the tumor mass. In cases of an aggressive form of diffuse-type gastric cancer called linitis plastica  (
         <a class="graphic graphic_diagnosticimage graphicRef122999" href="/z/d/graphic/122999.html" rel="external">
          image 1
         </a>
         ), these symptoms arise from the inability of the stomach to distend. Patients may also present with gastric outlet obstruction from an advanced distal tumor.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Occult gastrointestinal bleeding, with or without iron deficiency anemia, is not uncommon, while overt bleeding (ie, melena or hematemesis) is seen in fewer than 20 percent of cases. The presence of a palpable abdominal mass, although uncommon, is the most common physical finding and generally indicates long-standing, advanced disease [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients may also present with signs or symptoms of distant metastatic disease. The most common sites of metastatic disease are the liver, the peritoneal surfaces, and the nonregional or distant lymph nodes. Less commonly, ovary, central nervous system (brain or leptomeningeal), bone, intrathoracic (pleural or parenchymal), or soft tissue metastases can occur:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In patients with lymphatic spread, the physical examination may reveal a left supraclavicular lymph node (Virchow's node [
         <a href="#rid3">
          3
         </a>
         ], which is the most common physical examination finding of metastatic disease), a periumbilical nodule (Sister Mary Joseph's node [
         <a href="#rid4">
          4
         </a>
         ]), or a left axillary node (Irish node).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Peritoneal spread can present with an enlarged ovary (Krukenberg tumor [
         <a href="#rid5">
          5
         </a>
         ]) or a mass in the cul-de-sac on rectal examination (Blumer's shelf [
         <a href="#rid6">
          6
         </a>
         ]). While there are patients with ovarian metastases without other peritoneal disease, these are usually a harbinger of later development of visible peritoneal disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Ascites can also be the first indication of peritoneal carcinomatosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A palpable liver mass can indicate metastases, although metastatic disease to the liver is often multifocal or diffuse. Liver involvement is often, but not always, associated with an elevation in the serum alkaline phosphatase concentration.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Jaundice or clinical evidence of liver failure, if seen, suggests advanced metastatic disease [
         <a href="#rid7">
          7
         </a>
         ]. However, jaundice is also occasionally seen with locally advanced distal tumors, and these patients typically also have gastric outlet obstruction.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         More rarely, patients with gastric cancer may present with complications that result from direct extension of the gastric cancer through the gastric wall. As an example, feculent emesis or passage of recently ingested material in the stool can be seen with malignant gastrocolic fistula, although this is quite rare. More commonly, colonic obstruction may occur.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Paraneoplastic manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Systemic manifestations of gastric cancer related to paraneoplastic phenomena are rarely seen at initial presentation. Dermatologic findings may include the sudden appearance of diffuse seborrheic keratoses (sign of Leser-Trélat) [
         <a href="#rid8">
          8
         </a>
         ] or acanthosis nigricans [
         <a href="#rid9">
          9
         </a>
         ], which is characterized by velvety and darkly pigmented patches on skin folds. Neither finding is specific for gastric cancer, and they may be associated with other gastrointestinal malignancies or simply a benign process. (See
         <a class="medical medical_review" href="/z/d/html/7606.html" rel="external">
          "Cutaneous manifestations of internal malignancy", section on 'Hyperkeratotic and proliferative dermatoses'
         </a>
         .)
        </p>
        <p>
         Other paraneoplastic abnormalities that can occur in gastric cancer include a microangiopathic hemolytic anemia [
         <a href="#rid10">
          10
         </a>
         ], membranous nephropathy [
         <a href="#rid11">
          11
         </a>
         ], and hypercoagulable states (Trousseau's syndrome) [
         <a href="#rid12">
          12
         </a>
         ]. Like with most advanced gastrointestinal malignancies, gastric cancer patients can develop pulmonary emboli. Polyarteritis nodosa has been reported as the single manifestation of an early and surgically curable gastric cancer [
         <a href="#rid13">
          13
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3050.html" rel="external">
          "Membranous nephropathy: Pathogenesis and etiology"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1352.html" rel="external">
          "Risk and prevention of venous thromboembolism in adults with cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8245.html" rel="external">
          "Clinical manifestations and diagnosis of polyarteritis nodosa in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2006087988">
         <span class="h1">
          IMAGING FINDINGS
         </span>
        </p>
        <p class="headingAnchor" id="H3351966400">
         <span class="h2">
          Cross-sectional imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with a suspected gastric cancer, contrast-enhanced computed tomography (CT) imaging provides information about the primary tumor, and it can also visualize low-volume ascites, peritoneal metastases, liver metastases, and perigastric and distant nodal disease. The CT appearance of a proximal gastric cancer can be illustrated by the figure  (
         <a class="graphic graphic_diagnosticimage graphicRef123000" href="/z/d/graphic/123000.html" rel="external">
          image 2
         </a>
         ). The CT appearance of a distal tumor is provided separately  (
         <a class="graphic graphic_diagnosticimage graphicRef123001" href="/z/d/graphic/123001.html" rel="external">
          image 3
         </a>
         ). (See
         <a class="local">
          'Computed tomography scan in all patients'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H136925718">
         <span class="h2">
          Barium studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">
          Barium
         </a>
         studies can identify both malignant gastric ulcers and infiltrating lesions  (
         <a class="graphic graphic_diagnosticimage graphicRef123010" href="/z/d/graphic/123010.html" rel="external">
          image 4
         </a>
         ), and some early gastric cancers may also be seen. However, false-negative barium studies can occur in as much as 50 percent of cases [
         <a href="#rid14">
          14
         </a>
         ]. This is a particular problem in early gastric cancer, where the sensitivity of barium studies may be as low as 14 percent [
         <a href="#rid15">
          15
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2520.html" rel="external">
          "Early gastric cancer: Epidemiology, clinical manifestations, diagnosis, and staging"
         </a>
         .)
        </p>
        <p>
         Given the widespread availability of upper endoscopy and contrast-enhanced CT scans, it is extremely rare in our experience to see a patient whose tumor was initially suspected based on a
         <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">
          barium
         </a>
         study.
        </p>
        <p>
         The one scenario in which a
         <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">
          barium
         </a>
         study may be superior to upper endoscopy for diagnostic evaluation is in patients with linitis plastica. The decreased distensibility of the stiff, "leather-flask" appearing stomach is more obvious on barium study, and the endoscopic appearance may be relatively normal. However, clinical staging and histologic confirmation require endoscopic evaluation, typically endoscopic ultrasound (EUS). (See
         <a class="local">
          'Endoscopic ultrasound'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          DIAGNOSIS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          When to suspect the diagnosis
         </strong>
         – The diagnosis of gastric cancer may be suspected in patients with abdominal pain or weight loss and a history of gastric ulcer, or because of findings on upper endoscopy or radiographic imaging (eg, abdominal computed tomography [CT] or
         <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">
          barium
         </a>
         studies). However, histologic examination of gastric tumor tissue is required to establish the diagnosis; this is almost always acquired with endoscopic biopsies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Endoscopic appearance
         </strong>
         – Tissue diagnosis and anatomic localization of the primary tumor are best obtained by upper gastrointestinal endoscopy. The early use of upper endoscopy in patients presenting with gastrointestinal complaints may be associated with a higher rate of detection of early gastric cancers. (See
         <a class="medical medical_review" href="/z/d/html/2481.html" rel="external">
          "Surgical management of invasive gastric cancer", section on 'Early diagnosis of gastric cancer'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The typical appearance of gastric cancer is a friable, ulcerated mass  (
         <a class="graphic graphic_picture graphicRef58136 graphicRef71672" href="/z/d/graphic/58136.html" rel="external">
          picture 1A-B
         </a>
         ). In patients with a gastric ulcer, the presence of folds surrounding the ulcer crater that are nodular, clubbed, fused, or stop short of the ulcer margin, and the presence of overhanging, irregular, or thickened ulcer margins are also suggestive of a malignant ulcer. (See
         <a class="medical medical_review" href="/z/d/html/26.html" rel="external">
          "Peptic ulcer disease: Clinical manifestations and diagnosis", section on 'Malignant appearing ulcers'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The gastric mucosa may appear normal in patients with linitis plastica, a particularly aggressive form of diffuse-type gastric cancer. Tumors with extensive submucosal spread (the linitis plastica appearance  (
         <a class="graphic graphic_diagnosticimage graphicRef122999" href="/z/d/graphic/122999.html" rel="external">
          image 1
         </a>
         )) can be difficult endoscopically; in fact, this is responsible for the vast majority of gastric cancers for which upper endoscopy is nondiagnostic. These tumors tend to infiltrate the submucosa and muscularis propria extensively, and there may be no superficial mucosal findings. Poor distensibility of the stomach may be the only finding on endoscopic evaluation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Biopsy technique
         </strong>
         – During endoscopy, any suspicious-appearing gastric ulceration should be biopsied. Since up to 5 percent of malignant ulcers appear benign grossly, it is imperative that all such lesions be evaluated with biopsy and histologic assessment [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We obtain biopsies using jumbo forceps and sampling the edges of the ulcer. A single biopsy has a 70 percent sensitivity for diagnosing an existing gastric cancer, while performing seven biopsies from the ulcer margin and base increases the sensitivity to greater than 98 percent [
         <a href="#rid16">
          16
         </a>
         ]. While it is clear that any suspicious-appearing lesion requires biopsy, it may be even more important to take numerous biopsies from smaller, benign-appearing gastric ulcers, especially in patients at high risk for gastric cancer, since the diagnosis of early gastric cancer offers the greatest opportunity for surgical cure and long-term survival. (See
         <a class="medical medical_review" href="/z/d/html/2520.html" rel="external">
          "Early gastric cancer: Epidemiology, clinical manifestations, diagnosis, and staging"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/26.html" rel="external">
          "Peptic ulcer disease: Clinical manifestations and diagnosis", section on 'Selected benign appearing ulcers'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Because these tumors tend to infiltrate the submucosa and muscularis propria, superficial mucosal biopsies may be falsely negative. For this reason, the combination of strip and bite biopsy techniques should be used when there is suspicion of a diffuse type of gastric cancer [
         <a href="#rid17">
          17
         </a>
         ]. Jumbo biopsies are also employed when this is suspected. (See
         <a class="local">
          'Barium studies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If bleeding with biopsy is of concern to the endoscopist, it is reasonable to brush the ulcer base, since the risk of bleeding from this technique is negligible. Brush cytology increases the sensitivity of a single biopsy, but the extent to which it enhances diagnostic yield when seven biopsies are obtained remains unknown [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          STAGING EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with documented gastric cancer should undergo a complete staging evaluation in order to guide therapy and more reliably predict outcome. Careful staging allows the clinician to select the most appropriate therapy, minimizes unnecessary surgery, and maximizes the likelihood of benefit from the selected treatment.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Staging systems
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are two major classification systems in use for gastric cancer. The more elaborate Japanese classification is based on refined anatomic location, particularly of the lymph node stations [
         <a href="#rid19">
          19
         </a>
         ]. The other and more widely used staging system, developed jointly by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC), is the classification most often used in the Western hemisphere and is now commonly used in Asian countries, including Japan, as well.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          TNM staging criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         The staging schema of the AJCC/UICC is based on tumor, node, metastasis (TNM) classifications.
        </p>
        <p>
         The most recent revision of the AJCC/UICC TNM staging classification (eighth edition, 2017) includes separate prognostic stage groups for clinical and pathologic staging, including pathologic staging following a course of neoadjuvant therapy (yp stage)  (
         <a class="graphic graphic_table graphicRef111190" href="/z/d/graphic/111190.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid20">
          20
         </a>
         ]. This change is a reflection of the dramatically changed landscape of the use of neoadjuvant therapy for gastric cancer in this country, as well as around the world over the past 15 years  (
         <a class="graphic graphic_figure graphicRef123027" href="/z/d/graphic/123027.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid21">
          21
         </a>
         ]. The stratification in overall survival according to pathologic stage in the absence of neoadjuvant therapy and following neoadjuvant therapy, respectively, is depicted in the figures  (
         <a class="graphic graphic_figure graphicRef111192" href="/z/d/graphic/111192.html" rel="external">
          figure 3
         </a>
         and
         <a class="graphic graphic_figure graphicRef111193" href="/z/d/graphic/111193.html" rel="external">
          figure 4
         </a>
         ) [
         <a href="#rid20">
          20,22
         </a>
         ].
        </p>
        <p>
         A notable omission is the lack of classification for a ypT0N0 tumor in this system. A modification to the postneoadjuvant pathologic staging system has been proposed, but is not in widespread use [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
         One of the most important changes from the earlier 2010 classification is a redefinition of the boundary between esophageal and gastric cancers. Tumors involving the esophagogastric junction (EGJ) with the tumor epicenter no more than 2 cm into the proximal stomach are staged as esophageal rather than gastric cancers  (
         <a class="graphic graphic_table graphicRef111221" href="/z/d/graphic/111221.html" rel="external">
          table 3
         </a>
         ). In contrast, EGJ tumors with their epicenter located more than 2 cm into the proximal stomach are staged as stomach cancers. (See
         <a class="medical medical_review" href="/z/d/html/2502.html" rel="external">
          "Clinical manifestations, diagnosis, and staging of esophageal cancer", section on 'TNM staging criteria'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16226.html" rel="external">
          "Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas", section on 'AJCC classification'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16226.html" rel="external">
          "Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas", section on 'Siewert classification'
         </a>
         .)
        </p>
        <p>
         The regional nodes for tumors involving different parts of the stomach are depicted in the figure  (
         <a class="graphic graphic_figure graphicRef111191" href="/z/d/graphic/111191.html" rel="external">
          figure 5
         </a>
         ). Involvement of other intra-abdominal nodal groups (ie, pancreatoduodenal, retropancreatic, peripancreatic, superior mesenteric, middle colic, para-aortic, and retroperitoneal) is classified as distant metastasis [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          Treatment implications of clinical staging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although prognosis is most accurately determined by the surgical pathology after tumor resection, the clinical stage directs the initial approach to therapy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients who appear to have locoregional disease
         </strong>
         (stage I to III  (
         <a class="graphic graphic_table graphicRef111190" href="/z/d/graphic/111190.html" rel="external">
          table 2
         </a>
         )) after preoperative testing are potentially curable; all patients with a primary tumor that is considered to invade through the submucosa (T2 or higher) or with a high suspicion of nodal involvement on pretreatment staging studies should be referred for multidisciplinary evaluation to identify the best treatment strategy (ie, upfront surgery versus initial chemotherapy or chemoradiotherapy). Adjuvant and neoadjuvant treatment for gastric and esophagogastric junction cancer and surgical management of gastric cancer, including criteria for surgical resectability, are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2523.html" rel="external">
          "Adjuvant and neoadjuvant treatment of gastric cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2481.html" rel="external">
          "Surgical management of invasive gastric cancer", section on 'Adjuvant and neoadjuvant therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16226.html" rel="external">
          "Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with locally advanced unresectable, or advanced stage IV disease
         </strong>
         are usually referred for palliative therapy depending on their symptoms and functional status. Multiple studies indicate both longer survival and better quality of life with systemic treatment (see
         <a class="medical medical_review" href="/z/d/html/2473.html" rel="external">
          "Initial systemic therapy for locally advanced unresectable and metastatic esophageal and gastric cancer"
         </a>
         ). Invasion of a major vascular structure, such as the aorta, or disease encasement or occlusion of the hepatic artery or celiac axis/proximal splenic artery is widely considered to represent locally advanced, unresectable disease. In approximately 5 percent of primary gastric cancers, a broad region of the gastric wall, or even the entire stomach, is extensively infiltrated by malignancy, resulting in a rigid, thickened stomach, termed linitis plastica  (
         <a class="graphic graphic_diagnosticimage graphicRef122999" href="/z/d/graphic/122999.html" rel="external">
          image 1
         </a>
         ). Linitis plastica has an extremely poor prognosis, and many surgeons consider the presence of linitis plastica to be a contraindication to potentially curative resection, even in the absence of other indicators of unresectability. At some institutions, these patients may be considered candidates for extended neoadjuvant therapy. We typically will administer four to six months of chemotherapy and, if no evidence of progression, will follow with chemoradiotherapy. If after the completion of this, there is no evidence of distant disease, resection is considered. (See
         <a class="medical medical_review" href="/z/d/html/2481.html" rel="external">
          "Surgical management of invasive gastric cancer", section on 'Linitis plastica'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The goal of the staging evaluation is to initially stratify patients into two clinical groups in order to guide management: those with locoregional, potentially resectable (stage I to III  (
         <a class="graphic graphic_table graphicRef111190" href="/z/d/graphic/111190.html" rel="external">
          table 2
         </a>
         )) disease and those with either locally advanced, unresectable or metastatic (stage IV) disease. (See
         <a class="local">
          'Treatment implications of clinical staging'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1796953294">
         <span class="h3">
          Suggested approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         The ultimate choice of staging modality is dependent on the clinical scenario and local expertise. Our suggested approach, which is generally consistent with guidelines from the National Comprehensive Cancer Network (NCCN) [
         <a href="#rid24">
          24
         </a>
         ] and the European Society for Medical Oncology (ESMO) [
         <a href="#rid25">
          25
         </a>
         ], is provided in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef123082" href="/z/d/graphic/123082.html" rel="external">
          algorithm 1
         </a>
         ) and summarized as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Computed tomography (CT) scans of the chest, abdomen, and pelvis are indicated in all patients with gastric cancer to evaluate for metastatic disease (M stage). Abdominal CT scans should not be relied on for assessing tumor depth (T stage), the presence or absence of lymph node involvement (N stage), or the presence of peritoneal metastases, although they can alert the clinician that further assessment may be necessary. (See
         <a class="local">
          'Additional tests in selected patients'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         While thickening of the wall of the stomach may be related to tumors, it should be considered cautiously. The degree of distension of the stomach has a dramatic impact on wall thickness in general. There are other causes of gastric wall thickening besides gastric adenocarcinoma, both benign and malignant, that one should be aware of but are beyond the scope of this topic review.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Suspicious intrathoracic findings, visceral (hepatic) lesions, omental or peritoneal masses, or retroperitoneal lymph nodes require biopsy confirmation. Indeterminate hepatic lesions may be further evaluated with magnetic resonance imaging (MRI) or ultrasound if indicated. Paracentesis should be performed when ascites is detected, and the fluid should be sent for cytology and standard chemical analysis. CT imaging may also reveal bone metastases in some patients with advanced disease. In patients who present with bone pain, evaluation with a bone scan may be considered. (See
         <a class="medical medical_review" href="/z/d/html/1261.html" rel="external">
          "Evaluation of adults with ascites", section on 'Determining the cause of the ascites'
         </a>
         and
         <a class="local">
          'Computed tomography scan in all patients'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For most patients with gastric cancer who have no radiographic evidence of metastatic (M1) disease, we recommend endoscopic ultrasound (EUS) for assessment of T and N stage. (See
         <a class="local">
          'Endoscopic ultrasound'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For most patients with clinical stage ≥T2N0 disease and a radiographic staging evaluation that is negative for metastatic disease, we perform integrated positron emission tomography (PET)/CT to screen for distant metastases. As with CT, suspicious lesions may warrant biopsy. (See
         <a class="local">
          '18-fluorodeoxyglucose positron emission tomography scan'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For most patients, we recommend pretreatment staging laparoscopy to detect occult peritoneal dissemination in any medically fit patient who appears to have more than a T1a lesion on EUS, who has no histologic confirmation of stage IV disease, and who would not otherwise require palliative gastrectomy because of symptoms. (See
         <a class="local">
          'Staging laparoscopy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum tumor markers (including carcinoembryonic antigen [CEA] and the glycoprotein cancer antigen 125 [CA 125]) are of limited utility, and we do not routinely assay for them preoperatively, unless a patient is undergoing neoadjuvant therapy. (See
         <a class="local">
          'Serologic markers'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For certain patients, such as those with an obstructing or significantly bleeding distal gastric cancer with no evidence of metastases by CT scan, it may be reasonable to directly proceed to surgery without further testing.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h3">
          Computed tomography scan in all patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients in whom a gastric cancer is suspected or histologically confirmed should undergo cross-sectional imaging of the chest, abdomen, and pelvis, typically with a contrast-enhanced (typically oral plus IV) CT scan. CT is widely available, is noninvasive, and is well suited to evaluating widely metastatic disease, especially hepatic or adnexal metastases, ascites, or distant nodal spread. Patients who have CT-defined visceral metastatic disease can avoid unnecessary surgery, although biopsy confirmation is recommended because of the risk of false-positive findings.
        </p>
        <p>
         However, peritoneal metastases and hematogenous metastases smaller than 5 mm are frequently missed by CT, even using modern CT techniques [
         <a href="#rid26">
          26
         </a>
         ]. In 20 to 30 percent of patients with a negative CT, intraperitoneal disease (including positive peritoneal washings) will be found at either staging laparoscopy or at open exploration [
         <a href="#rid27">
          27-29
         </a>
         ].
        </p>
        <p>
         Another limitation of CT is its inability to accurately assess the depth of primary tumor invasion (particularly with small tumors) and the presence of lymph node involvement. CT accurately assesses the T stage of the primary tumor in only approximately 50 to 70 percent of cases, typically for more advanced cases  (
         <a class="graphic graphic_diagnosticimage graphicRef128358" href="/z/d/graphic/128358.html" rel="external">
          image 5
         </a>
         ) [
         <a href="#rid30">
          30-36
         </a>
         ]. More often, the tumor is understaged because the depth of invasion is underestimated; however, overstaging also occurs.
        </p>
        <p>
         The classification of nodal status is usually based on lymph node size, and the sensitivity of CT for detecting regional nodal metastases is limited for involved nodes that are smaller than 0.8 cm [
         <a href="#rid30">
          30,35
         </a>
         ]. Furthermore, false-positive findings may be attributed to inflammatory lymphadenopathy. In series of patients undergoing staging CT for gastric cancer or gastric and esophageal cancer, sensitivity and specificity rates for regional nodal metastases range from 65 to 97 percent and from 49 to 90 percent, respectively [
         <a href="#rid37">
          37-41
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1068386611">
         <span class="h3">
          Additional tests in selected patients
         </span>
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h4">
          Endoscopic ultrasound
         </span>
         <span class="headingEndMark">
          —
         </span>
         EUS is the most reliable nonsurgical method available for evaluating the depth of invasion of primary gastric cancers. EUS is recommended by both the NCCN and ESMO for pretreatment evaluation of all patients with gastric cancer who have no radiographic evidence of metastatic (M1) disease and have otherwise potentially operable disease [
         <a href="#rid24">
          24,25
         </a>
         ]. (See
         <a class="local">
          'Suggested approach'
         </a>
         above.)
        </p>
        <p>
         Accurate assessment of T and N stage  (
         <a class="graphic graphic_table graphicRef111190" href="/z/d/graphic/111190.html" rel="external">
          table 2
         </a>
         ) is important for treatment selection. As examples, in patients with early gastric cancer, accurate assessment of submucosal invasion is essential before considering the option of endoscopic mucosal resection. Neoadjuvant chemotherapy or chemoradiotherapy may be recommended for patients with a primary tumor that is considered to invade into the muscularis propria (T2 or higher) or with a high suspicion of nodal involvement on pretreatment staging studies. (See
         <a class="medical medical_review" href="/z/d/html/2523.html" rel="external">
          "Adjuvant and neoadjuvant treatment of gastric cancer", section on 'Initially locally unresectable nonmetastatic disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2523.html" rel="external">
          "Adjuvant and neoadjuvant treatment of gastric cancer", section on 'Is there a role for neoadjuvant chemoradiotherapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16226.html" rel="external">
          "Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas", section on 'Patients not yet resected'
         </a>
         .)
        </p>
        <p>
         In a systematic review of studies comparing EUS staging versus histopathology, the sensitivity and specificity rates for distinguishing T1 from T2 cancers with EUS were 85 and 90 percent, respectively [
         <a href="#rid42">
          42
         </a>
         ]. The sensitivity and specificity rates for distinguishing T1/2 from T3/4 tumors were 86 and 90 percent, respectively. For metastatic involvement of lymph nodes, the sensitivity and specificity rates were 83 and 67 percent, respectively. There was significant between-study heterogeneity that could not be easily explained. However, as with any technical endeavor, there is a degree of variability in operator expertise, which could at least partially explain these findings. We have found an increasing number of patients presenting already having had an EUS. Without knowing the experience level of the endoscopist, it is vital to consider the entire patient's situation. For example, if a patient is reported as having a T1 tumor, which may be amenable for upfront surgery or endoscopic mucosal dissection, yet presented with a GI bleed, this clinical dissonance should be further evaluated. Furthermore, an analysis of positive and negative likelihood ratios revealed that EUS diagnostic performance was favorable for neither exclusion nor confirmation of nodal positivity. Thus, EUS alone cannot be considered optimal for distinguishing positive from negative lymph node status.
        </p>
        <p>
         EUS is better than CT at assessing tumor depth (T stage) and perhaps lymph node involvement (N stage), particularly if fine-needle aspiration (FNA) is also performed. In comparative studies of preoperative staging, EUS generally provides a more accurate prediction of T stage than does CT [
         <a href="#rid43">
          43-46
         </a>
         ], although newer CT techniques (such as three-dimensional, multidetector row CT) and MRI may achieve similar results in terms of diagnostic accuracy in T staging [
         <a href="#rid41">
          41,47,48
         </a>
         ]. In contrast, accuracy for nodal staging is only slightly greater for EUS as compared with CT [
         <a href="#rid43">
          43,49-54
         </a>
         ]. EUS-guided FNA of suspicious nodes and regional areas adds to the accuracy of nodal staging [
         <a href="#rid55">
          55
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2656.html" rel="external">
          "Endoscopic ultrasound-guided fine needle aspiration in the gastrointestinal tract"
         </a>
         .)
        </p>
        <p>
         EUS is a relatively low-risk procedure, although it is more invasive than CT. One review quoted a risk of serious complications of 0.3 percent, most of which occurred in the setting of obstructing esophageal tumors [
         <a href="#rid56">
          56
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2663.html" rel="external">
          "Endoscopic ultrasound for evaluating patients with esophageal cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H354929113">
         <span class="h4">
          18-fluorodeoxyglucose positron emission tomography scan
         </span>
         <span class="headingEndMark">
          —
         </span>
         The role of 18-fluorodeoxyglucose (FDG)-PET in the staging evaluation of gastric cancer continues to evolve. We have become more selective in our use of PET imaging. Previously, we used it liberally in any patient with ≥T2N0 disease despite a negative CT. With the current high quality of contrast-enhanced CT imaging, we have found decreasing yield with the expanded use of PET. This is particularly true for diffuse type tumors where significant numbers of patients have tumors that are not FDG avid. Further, for patients with signet ring cell histology, the peritoneum is the most common site of metastatic disease; a site which we find better assessed by laparoscopy with washings [
         <a href="#rid57">
          57
         </a>
         ]. Generally we reserve PET-CT for those patients who have equivocal findings on CT imaging or patients with clinical indications of possible metastatic disease and otherwise negative imaging. This practice is consistent with NCCN and ESMO guidelines [
         <a href="#rid24">
          24,25
         </a>
         ].
        </p>
        <p>
         FDG-PET is more sensitive than CT for the detection of distant metastases, and FDG-PET/CT is positive in 6 to 16 percent of cases in most reports  (
         <a class="graphic graphic_diagnosticimage graphicRef97799" href="/z/d/graphic/97799.html" rel="external">
          image 6
         </a>
         ) [
         <a href="#rid58">
          58-62
         </a>
         ]. In one representative prospective study, integrated PET/CT identified otherwise radiographically occult metastatic lesions in approximately 10 percent of patients with locally advanced gastric cancer (≥T3 or ≥N1 disease  (
         <a class="graphic graphic_table graphicRef111190" href="/z/d/graphic/111190.html" rel="external">
          table 2
         </a>
         )) [
         <a href="#rid59">
          59
         </a>
         ]. However, others note a lower detection rate for detecting distant metastatic disease (3 percent), with limited sensitivity (33 percent), a high number of incidental findings, and significant overlap with findings at staging laparoscopy [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
         From the standpoint of locoregional staging, integrated PET/CT imaging can be useful to confirm malignant involvement of CT-detected lymphadenopathy [
         <a href="#rid64">
          64
         </a>
         ]. However, this usually does not impact the decision to proceed to surgery.
        </p>
        <p>
         FDG-PET has some important limitations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The sensitivity of PET scanning for peritoneal carcinomatosis is only approximately 50 percent [
         <a href="#rid65">
          65
         </a>
         ]. It is therefore not an adequate replacement for staging laparoscopy. (See
         <a class="local">
          'Staging laparoscopy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         PET/CT is only helpful if the tumor is FDG avid  (
         <a class="graphic graphic_diagnosticimage graphicRef122999" href="/z/d/graphic/122999.html" rel="external">
          image 1
         </a>
         ). A negative PET is therefore not helpful, since even large tumors with a diameter of several centimeters can be falsely negative if the tumor cells have a fairly low metabolic activity or are not FDG avid. Notably, many diffuse-type gastric cancers (signet ring carcinomas) are not FDG avid [
         <a href="#rid58">
          58,63,66-69
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h4">
          Staging laparoscopy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our practice is to use pretreatment staging laparoscopy to detect occult peritoneal dissemination in any medically fit patient who appears to have more than a T1a lesion on EUS, who has no histologic confirmation of stage IV disease, and who would not otherwise require palliative gastrectomy because of symptoms. Diagnostic laparoscopy should also be undertaken in any patient who is being considered for neoadjuvant therapy. Our approach is consistent with NCCN guidelines [
         <a href="#rid24">
          24
         </a>
         ] but differs slightly from ESMO guidelines (which suggest diagnostic laparoscopy, with or without peritoneal washings, for all stage IB to III tumors that are considered potentially resectable) [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
         Other experts disagree, suggesting that only patients with EUS stage T3/4 disease should undergo diagnostic staging laparoscopy because of the greater yield found than in patients with earlier stage disease [
         <a href="#rid29">
          29
         </a>
         ]. However, we believe that there is sufficient difficulty in the distinction between T2 and T3 lesions on EUS to warrant making decisions for or against staging laparoscopy based on EUS differentiation between T2 and T3 stages. (See
         <a class="medical medical_review" href="/z/d/html/15106.html" rel="external">
          "Diagnostic staging laparoscopy for digestive system cancers", section on 'Esophagogastric junction and gastric cancer'
         </a>
         .)
        </p>
        <p>
         Laparoscopy, while more invasive than CT or EUS, has the advantage of directly visualizing the liver surface and the peritoneum and can be used to examine local lymph nodes. Between 20 and 30 percent of patients who have disease that is beyond T1 stage on EUS will be found to have peritoneal metastases despite having a negative CT scan [
         <a href="#rid27">
          27-29,70,71
         </a>
         ]. The risk of finding occult peritoneal dissemination is even higher for certain subsets of patients, including those with advanced (T4) primary tumors or a linitis plastica appearance [
         <a href="#rid72">
          72
         </a>
         ]. In such cases, performance of a diagnostic laparoscopy frequently alters management (typically by avoiding unnecessary laparotomy) and may do so in up to one-half of patients [
         <a href="#rid72">
          72,73
         </a>
         ]. As noted previously, the sensitivity of PET scans for the detection of peritoneal carcinomatosis is only approximately 50 percent. (See
         <a class="medical medical_review" href="/z/d/html/2523.html" rel="external">
          "Adjuvant and neoadjuvant treatment of gastric cancer"
         </a>
         and
         <a class="local">
          '18-fluorodeoxyglucose positron emission tomography scan'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2481.html" rel="external">
          "Surgical management of invasive gastric cancer", section on 'Linitis plastica'
         </a>
         .)
        </p>
        <p>
         Another advantage of laparoscopy is the opportunity to perform peritoneal cytology or washings in patients who have no visible evidence of peritoneal spread. In most (but not all [
         <a href="#rid74">
          74
         </a>
         ]) series, this is a poor prognostic sign, even in the absence of overt peritoneal dissemination, and predicts for early peritoneal relapse [
         <a href="#rid75">
          75-77
         </a>
         ]. The vast majority of patients who are found to have peritoneal disease on laparoscopy will never require laparotomy or resection. The preference for laparoscopy over exploratory laparotomy to assess the peritoneal cavity cannot be overstated due to the substantially lower morbidity of laparoscopy. However, at some institutions (including our own), for patients with a positive peritoneal cytology in the absence of other evidence of intra-abdominal disease, a more nuanced approach is used. (See
         <a class="medical medical_review" href="/z/d/html/2481.html" rel="external">
          "Surgical management of invasive gastric cancer", section on 'Significance of positive peritoneal cytology'
         </a>
         .)
        </p>
        <p>
         Diagnostic laparoscopy is especially important for patients who are being considered for neoadjuvant therapy trials. At our institution, we routinely obtain peritoneal washings during laparoscopy in patients who lack visible peritoneal disease. We refer patients with a positive cytology in the absence of other evidence of metastatic disease for neoadjuvant approaches with more intensive chemotherapy than is used in the typical neoadjuvant setting. If at the completion of this, they remain free of visible disease, they would undergo chemoradiotherapy. They would then undergo staging laparoscopy with repeat washings and, if free of metastatic disease, would be considered for resection. (See
         <a class="medical medical_review" href="/z/d/html/2481.html" rel="external">
          "Surgical management of invasive gastric cancer", section on 'Neoadjuvant chemotherapy and chemoradiotherapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1903093870">
         <span class="h4">
          Serologic markers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serum tumor markers (including CEA and CA 125) are of limited utility in selected patients. Low rates of sensitivity and specificity prevent the use of any of these serologic markers as diagnostic tests for gastric cancer.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CEA, CA 125, CA 19-9, and CA 72-4
         </strong>
         – Serum levels of CEA, CA 125, carbohydrate antigen 19-9 (CA 19-9; also called cancer antigen 19-9), and cancer antigen 72-4 (CA 72-4) may be elevated in patients with gastric cancer [
         <a href="#rid78">
          78-82
         </a>
         ]. However, we do not routinely assay for them preoperatively, unless a patient is undergoing neoadjuvant therapy on trial. In a minority of patients, a drop in an elevated level of CEA and/or CA 125 may correlate with response to preoperative therapy, but clinical decisions are almost never made based on tumor marker changes alone. Likewise, in many [
         <a href="#rid83">
          83-93
         </a>
         ] (but not all [
         <a href="#rid81">
          81,94
         </a>
         ]) studies, preoperative elevations in serum tumor markers are an independent indicator of adverse prognosis. However, no serologic finding should be used to exclude a patient from surgical consideration. Recommendations for preoperative evaluation and staging of gastric cancer from the NCCN [
         <a href="#rid24">
          24
         </a>
         ] do not include assay of any tumor marker.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alpha-fetoprotein
         </strong>
         – Some gastric cancers are associated with elevated serum levels of alpha-fetoprotein (AFP); they are referred to as AFP-producing gastric cancers [
         <a href="#rid95">
          95-98
         </a>
         ]. A subset, hepatoid adenocarcinoma of the stomach, has a histologic appearance that is similar to that of hepatocellular cancer. Regardless of morphology, AFP-producing gastric cancers are aggressive and associated with a poor prognosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pepsinogen
         </strong>
         – Increases in serum pepsinogen II or decreases in the pepsinogen I to pepsinogen II ratio have been used in population screening programs to identify patients at increased risk for gastric cancer, but they are insufficiently sensitive or specific to establish a diagnosis in an individual patient. (See
         <a class="medical medical_review" href="/z/d/html/29.html" rel="external">
          "Gastritis: Etiology and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3644601445">
         <span class="h1">
          REFERRAL FOR GENETIC TESTING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although most gastric cancers are sporadic, aggregation within families occurs in approximately 10 percent of cases. Truly hereditary (familial) gastric cancer accounts for 1 to 3 percent of the global burden of gastric cancer and comprises at least three major syndromes: hereditary diffuse gastric cancer (HDGC), gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS), and familial intestinal gastric cancer (FIGC). The risk of developing gastric cancer is high in these families, but only HDGC is genetically explained  (
         <a class="graphic graphic_table graphicRef101357" href="/z/d/graphic/101357.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid99">
          99
         </a>
         ]. Guidelines from the International Gastric Cancer Linkage Consortium (IGCLC) and others recommend referral for genetic counseling and DNA testing for cadherin 1 (
         <em>
          CDH1
         </em>
         ) mutations and large rearrangements in patients with diffuse gastric cancer who have one or more of the following [
         <a href="#rid100">
          100,101
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/2511.html" rel="external">
          "Hereditary diffuse gastric cancer", section on 'Criteria for genetic testing'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Family history of two gastric cancers, at any age, with at least one confirmed diffuse gastric cancer
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diffuse gastric cancer diagnosed at age &lt;40 years, regardless of family history
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Personal or family history of diffuse gastric cancer and lobular breast cancer, with at least one diagnosed at &lt;50 years of age
        </p>
        <p>
        </p>
        <p>
         In addition, families in whom testing could be considered include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bilateral lobular breast cancer or family history (first- or second-degree relative) of two or more cases of lobular breast cancer &lt;50
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A personal or family history (first- or second-degree relative) of cleft lip/palate in a patient with diffuse gastric cancer
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An individual with in situ signet ring cells and/or pagetoid spread of signet ring cells on a gastric biopsy
        </p>
        <p>
        </p>
        <p>
         IGCLC guidelines are currently under revision, and publication of these are expected sometime in 2020.
        </p>
        <p class="headingAnchor" id="H3078384358">
         <span class="h1">
          ISSUES RELATED TO HELICOBACTER PYLORI INFECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infection with
         <em>
          Helicobacter pylori
         </em>
         is a major risk factor for gastric cancer. Individuals with gastric cancer should be screened for
         <em>
          H. pylori
         </em>
         infection and treated if positive. At least in the setting of early gastric cancer,
         <em>
          H. pylori
         </em>
         infection is associated with the development of metachronous gastric cancers, and eradication decreases the risk of developing metachronous gastric cancer after endoscopic treatment. (See
         <a class="medical medical_review" href="/z/d/html/16858.html" rel="external">
          "Early gastric cancer: Treatment, natural history, and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2353517750">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/114875.html" rel="external">
          "Society guideline links: Gastric cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H266239004">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/83156.html" rel="external">
          "Patient education: Stomach cancer (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/15732.html" rel="external">
          "Patient education: Upper endoscopy (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topic (see
         <a class="medical medical_patient" href="/z/d/html/1992.html" rel="external">
          "Patient education: Upper endoscopy (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features and diagnosis
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Most patients with gastric cancer are symptomatic, with weight loss and abdominal pain being the most common symptoms. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The diagnosis of gastric cancer may be suspected because of findings on upper endoscopy or radiographic studies, but histologic examination of tumor tissue (usually acquired endoscopically) is required to establish the diagnosis. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Staging and the staging workup
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The most commonly used staging schema for gastric cancer is that of the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC), which is based on tumor, node, metastasis (TNM) classifications  (
         <a class="graphic graphic_table graphicRef111190" href="/z/d/graphic/111190.html" rel="external">
          table 2
         </a>
         ). Tumors involving the esophagogastric junction (EGJ) with the tumor epicenter no more than 2 cm into the proximal stomach are staged as esophageal rather than gastric cancers, while EGJ tumors with their epicenter located more than 2 cm into the proximal stomach are staged as stomach cancers, as are all cardia cancers not involving the EGJ. (See
         <a class="local">
          'TNM staging criteria'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with documented gastric cancer should undergo a complete staging evaluation prior to surgical exploration in order to guide therapy and more reliably predict outcome. Our suggested approach is outlined in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef123082" href="/z/d/graphic/123082.html" rel="external">
          algorithm 1
         </a>
         ) and summarized as follows (see
         <a class="local">
          'Evaluation'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         CT scan of the chest, abdomen, and pelvis is indicated in all patients to look for metastatic disease (M stage); it should not be relied on for assessing tumor depth (T stage), lymph node involvement (N stage), or the definitive presence of peritoneal metastases. Suspicious visceral lesions, omental masses, or retroperitoneal lymph nodes require biopsy confirmation. Paracentesis should be performed when ascites is detected, and the fluid should be sent for cytology and standard chemical analysis. (See
         <a class="local">
          'Computed tomography scan in all patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Endoscopic ultrasound (EUS) is better than CT at assessing T stage and perhaps N stage, particularly if fine-needle aspiration (FNA) is also performed. An accurate assessment of T and N stage is important for treatment selection, particularly when selecting patients for neoadjuvant therapy rather than initial surgery. Consistent with guidelines from the NCCN and ESMO, we perform EUS for patients who have otherwise no evidence of metastatic (M1) disease. (See
         <a class="local">
          'Endoscopic ultrasound'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         The role of 18-fluorodeoxyglucose (FDG)-PET in the staging evaluation of gastric cancer continues to evolve. Diffuse type tumors are frequently not FDG avid, and for patients with signet ring cell histology, the peritoneum is the most common site of metastatic disease, and this is better assessed by laparoscopy with washings. In general, we reserve PET-CT for those patients with non-diffuse-type tumors who have equivocal findings on CT imaging or in those with clinical suspicion of possible metastatic disease with otherwise negative imaging. As with CT, suspicious lesions warrant biopsy. (See
         <a class="local">
          '18-fluorodeoxyglucose positron emission tomography scan'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Serum tumor markers (including carcinoembryonic antigen [CEA] and the glycoprotein cancer antigen 125 [CA 125]) are of limited utility, and we do not routinely assay for them, unless a patient is undergoing neoadjuvant therapy on trial. (See
         <a class="local">
          'Serologic markers'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Although others disagree, we advise preoperative staging laparoscopy for any medically fit patient who appears to have more than a T1a lesion on EUS, no histologic confirmation of stage IV disease, and would not otherwise require palliative gastrectomy. Diagnostic laparoscopy should also be undertaken in any patient who is being considered for neoadjuvant therapy. We routinely obtain peritoneal washings during laparoscopy in the absence of visible peritoneal disease. (See
         <a class="local">
          'Staging laparoscopy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For certain patients, such as those with an obstructing or significantly bleeding distal gastric cancer with no evidence of metastases by CT scan, it may be reasonable to directly proceed to surgery without further testing.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetic issues
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Gastric cancers are sporadic, though familial aggregation occurs in approximately 10 percent of cases. Truly hereditary (familial) gastric cancer accounts for 1 to 3 percent of the global burden of gastric cancer and comprises at least three major syndromes: hereditary diffuse gastric cancer (HDGC), gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS), and familial intestinal gastric cancer (FIGC). Only HDGC has a defined genetic basis  (
         <a class="graphic graphic_table graphicRef101357" href="/z/d/graphic/101357.html" rel="external">
          table 4
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Referral for genetic counseling and testing for cadherin
         <em>
          1 (CDH1
         </em>
         ) mutations and large rearrangements is recommended for individuals with diffuse gastric cancer who meet one or more of the following criteria (see
         <a class="local">
          'Referral for genetic testing'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Family history of two gastric cancers, at any age, with at least one confirmed diffuse gastric cancer.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Diffuse gastric cancer diagnosed at age &lt;40 years, regardless of family history.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Personal or family history of diffuse gastric cancer and lobular breast cancer, with at least one diagnosed at &lt;50 years of age.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           H. Pylori
          </em>
         </strong>
         – Individuals with gastric cancer and
         <em>
          H. pylori
         </em>
         should be screened for
         <em>
          H. pylori
         </em>
         infection and treated if positive. (See
         <a class="local">
          'Issues related to helicobacter pylori infection'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Wanebo HJ, Kennedy BJ, Chmiel J, et al. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg 1993; 218:583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kahrilas PJ, Kishk SM, Helm JF, et al. Comparison of pseudoachalasia and achalasia. Am J Med 1987; 82:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morgenstern L. The Virchow-Troisier node: a historical note. Am J Surg 1979; 138:703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pieslor PC, Hefter LG. Umbilical metastasis from prostatic carcinoma--Sister Joseph nodule. Urology 1986; 27:558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilliland R, Gill PJ. Incidence and prognosis of Krukenberg tumour in Northern Ireland. Br J Surg 1992; 79:1364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winne BURCHARD BE. Blumer's shelf tumor with primary carcinoma of the lung. A case report. J Int Coll Surg 1965; 44:477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fuchs CS, Mayer RJ. Gastric carcinoma. N Engl J Med 1995; 333:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dantzig PI. Sign of Leser-Trélat. Arch Dermatol 1973; 108:700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown J, Winkelmann RK. Acanthosis nigricans: a study of 90 cases. Medicine (Baltimore) 1968; 47:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antman KH, Skarin AT, Mayer RJ, et al. Microangiopathic hemolytic anemia and cancer: a review. Medicine (Baltimore) 1979; 58:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wakashin M, Wakashin Y, Iesato K, et al. Association of gastric cancer and nephrotic syndrome. An immunologic study in three patients. Gastroenterology 1980; 78:749.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sack GH Jr, Levin J, Bell WR. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore) 1977; 56:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poveda F, González-García J, Picazo ML, et al. Systemic polyarteritis nodosa as the initial manifestation of a gastric adenocarcinoma. J Intern Med 1994; 236:679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dooley CP, Larson AW, Stace NH, et al. Double-contrast barium meal and upper gastrointestinal endoscopy. A comparative study. Ann Intern Med 1984; 101:538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Longo WE, Zucker KA, Zdon MJ, Modlin IM. Detection of early gastric cancer in an aggressive endoscopy unit. Am Surg 1989; 55:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graham DY, Schwartz JT, Cain GD, Gyorkey F. Prospective evaluation of biopsy number in the diagnosis of esophageal and gastric carcinoma. Gastroenterology 1982; 82:228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karita M, Tada M. Endoscopic and histologic diagnosis of submucosal tumors of the gastrointestinal tract using combined strip biopsy and bite biopsy. Gastrointest Endosc 1994; 40:749.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang HH, Jonasson JG, Ducatman BS. Brushing cytology of the upper gastrointestinal tract. Obsolete or not? Acta Cytol 1991; 35:195.
          </a>
         </li>
         <li class="breakAll">
          The General Rules for the Gastric Cancer Study in Surgery and Pathology, 12th ed, Japanese Research Society for Gastric Cancer (Ed), Kanahara Shuppan, Tokyo 1993.
         </li>
         <li class="breakAll">
          Ajani JA, In H, Sano T, et al. Stomach. In: AJCC Cancer Staging Manual, 8th ed, Amin MB (Ed), AJCC, Chicago 2017. p.203.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ikoma N, Cormier JN, Feig B, et al. Racial disparities in preoperative chemotherapy use in gastric cancer patients in the United States: Analysis of the National Cancer Data Base, 2006-2014. Cancer 2018; 124:998.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sano T, Coit DG, Kim HH, et al. Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association staging project. Gastric Cancer 2017; 20:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin JX, Yoon C, Desiderio J, et al. Development and validation of a staging system for gastric adenocarcinoma after neoadjuvant chemotherapy and gastrectomy with D2 lymphadenectomy. Br J Surg 2019; 106:1187.
          </a>
         </li>
         <li class="breakAll">
          National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf (Accessed on July 25, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33:1005.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim SJ, Kim HH, Kim YH, et al. Peritoneal metastasis: detection with 16- or 64-detector row CT in patients undergoing surgery for gastric cancer. Radiology 2009; 253:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lowy AM, Mansfield PF, Leach SD, Ajani J. Laparoscopic staging for gastric cancer. Surgery 1996; 119:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feussner H, Omote K, Fink U, et al. Pretherapeutic laparoscopic staging in advanced gastric carcinoma. Endoscopy 1999; 31:342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Power DG, Schattner MA, Gerdes H, et al. Endoscopic ultrasound can improve the selection for laparoscopy in patients with localized gastric cancer. J Am Coll Surg 2009; 208:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davies J, Chalmers AG, Sue-Ling HM, et al. Spiral computed tomography and operative staging of gastric carcinoma: a comparison with histopathological staging. Gut 1997; 41:314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sussman SK, Halvorsen RA Jr, Illescas FF, et al. Gastric adenocarcinoma: CT versus surgical staging. Radiology 1988; 167:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdalla EK, Pisters PW. Staging and preoperative evaluation of upper gastrointestinal malignancies. Semin Oncol 2004; 31:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minami M, Kawauchi N, Itai Y, et al. Gastric tumors: radiologic-pathologic correlation and accuracy of T staging with dynamic CT. Radiology 1992; 185:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rossi M, Broglia L, Maccioni F, et al. Hydro-CT in patients with gastric cancer: preoperative radiologic staging. Eur Radiol 1997; 7:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Düx M, Richter GM, Hansmann J, et al. Helical hydro-CT for diagnosis and staging of gastric carcinoma. J Comput Assist Tomogr 1999; 23:913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee IJ, Lee JM, Kim SH, et al. Diagnostic performance of 64-channel multidetector CT in the evaluation of gastric cancer: differentiation of mucosal cancer (T1a) from submucosal involvement (T1b and T2). Radiology 2010; 255:805.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Elia F, Zingarelli A, Palli D, Grani M. Hydro-dynamic CT preoperative staging of gastric cancer: correlation with pathological findings. A prospective study of 107 cases. Eur Radiol 2000; 10:1877.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sohn KM, Lee JM, Lee SY, et al. Comparing MR imaging and CT in the staging of gastric carcinoma. AJR Am J Roentgenol 2000; 174:1551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kienle P, Buhl K, Kuntz C, et al. Prospective comparison of endoscopy, endosonography and computed tomography for staging of tumours of the oesophagus and gastric cardia. Digestion 2002; 66:230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wakelin SJ, Deans C, Crofts TJ, et al. A comparison of computerised tomography, laparoscopic ultrasound and endoscopic ultrasound in the preoperative staging of oesophago-gastric carcinoma. Eur J Radiol 2002; 41:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yan C, Zhu ZG, Yan M, et al. Value of multidetector-row computed tomography in the preoperative T and N staging of gastric carcinoma: a large-scale Chinese study. J Surg Oncol 2009; 100:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mocellin S, Pasquali S. Diagnostic accuracy of endoscopic ultrasonography (EUS) for the preoperative locoregional staging of primary gastric cancer. Cochrane Database Syst Rev 2015; :CD009944.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Willis S, Truong S, Gribnitz S, et al. Endoscopic ultrasonography in the preoperative staging of gastric cancer: accuracy and impact on surgical therapy. Surg Endosc 2000; 14:951.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meining A, Dittler HJ, Wolf A, et al. You get what you expect? A critical appraisal of imaging methodology in endosonographic cancer staging. Gut 2002; 50:599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeung HW, Macapinlac H, Karpeh M, et al. Accuracy of FDG-PET in Gastric Cancer. Preliminary Experience. Clin Positron Imaging 1998; 1:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris KM, Kelly S, Berry E, et al. Systematic review of endoscopic ultrasound in gastro-oesophageal cancer. Health Technol Assess 1998; 2:i.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhandari S, Shim CS, Kim JH, et al. Usefulness of three-dimensional, multidetector row CT (virtual gastroscopy and multiplanar reconstruction) in the evaluation of gastric cancer: a comparison with conventional endoscopy, EUS, and histopathology. Gastrointest Endosc 2004; 59:619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwee RM, Kwee TC. Imaging in local staging of gastric cancer: a systematic review. J Clin Oncol 2007; 25:2107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pollack BJ, Chak A, Sivak MV Jr. Endoscopic ultrasonography. Semin Oncol 1996; 23:336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly S, Harris KM, Berry E, et al. A systematic review of the staging performance of endoscopic ultrasound in gastro-oesophageal carcinoma. Gut 2001; 49:534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Botet JF, Lightdale CJ, Zauber AG, et al. Preoperative staging of gastric cancer: comparison of endoscopic US and dynamic CT. Radiology 1991; 181:426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fukuya T, Honda H, Hayashi T, et al. Lymph-node metastases: efficacy for detection with helical CT in patients with gastric cancer. Radiology 1995; 197:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Manzoni G, Pedrazzani C, Di Leo A, et al. Experience of endoscopic ultrasound in staging adenocarcinoma of the cardia. Eur J Surg Oncol 1999; 25:595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsendsuren T, Jun SM, Mian XH. Usefulness of endoscopic ultrasonography in preoperative TNM staging of gastric cancer. World J Gastroenterol 2006; 12:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang KJ, Katz KD, Durbin TE, et al. Endoscopic ultrasound-guided fine-needle aspiration. Gastrointest Endosc 1994; 40:694.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nickl NJ, Bhutani MS, Catalano M, et al. Clinical implications of endoscopic ultrasound: the American Endosonography Club Study. Gastrointest Endosc 1996; 44:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riihimäki M, Hemminki A, Sundquist K, et al. Metastatic spread in patients with gastric cancer. Oncotarget 2016; 7:52307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen J, Cheong JH, Yun MJ, et al. Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. Cancer 2005; 103:2383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smyth E, Schöder H, Strong VE, et al. A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer. Cancer 2012; 118:5481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bosch KD, Chicklore S, Cook GJ, et al. Staging FDG PET-CT changes management in patients with gastric adenocarcinoma who are eligible for radical treatment. Eur J Nucl Med Mol Imaging 2020; 47:759.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Findlay JM, Antonowicz S, Segaran A, et al. Routinely staging gastric cancer with 18F-FDG PET-CT detects additional metastases and predicts early recurrence and death after surgery. Eur Radiol 2019; 29:2490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serrano OK, Love C, Goldman I, et al. The value of FDG-PET in the staging of gastric adenocarcinoma: A single institution retrospective review. J Surg Oncol 2016; 113:640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gertsen EC, Brenkman HJF, van Hillegersberg R, et al. 18F-Fludeoxyglucose-Positron Emission Tomography/Computed Tomography and Laparoscopy for Staging of Locally Advanced Gastric Cancer: A Multicenter Prospective Dutch Cohort Study (PLASTIC). JAMA Surg 2021; 156:e215340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yun M, Lim JS, Noh SH, et al. Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT. J Nucl Med 2005; 46:1582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoshioka T, Yamaguchi K, Kubota K, et al. Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer. J Nucl Med 2003; 44:690.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Potter T, Flamen P, Van Cutsem E, et al. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. Eur J Nucl Med Mol Imaging 2002; 29:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stahl A, Ott K, Weber WA, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 2003; 30:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim SK, Kang KW, Lee JS, et al. Assessment of lymph node metastases using 18F-FDG PET in patients with advanced gastric cancer. Eur J Nucl Med Mol Imaging 2006; 33:148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mukai K, Ishida Y, Okajima K, et al. Usefulness of preoperative FDG-PET for detection of gastric cancer. Gastric Cancer 2006; 9:192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watt I, Stewart I, Anderson D, et al. Laparoscopy, ultrasound and computed tomography in cancer of the oesophagus and gastric cardia: a prospective comparison for detecting intra-abdominal metastases. Br J Surg 1989; 76:1036.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarela AI, Lefkowitz R, Brennan MF, Karpeh MS. Selection of patients with gastric adenocarcinoma for laparoscopic staging. Am J Surg 2006; 191:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simon M, Mal F, Perniceni T, et al. Accuracy of staging laparoscopy in detecting peritoneal dissemination in patients with gastroesophageal adenocarcinoma. Dis Esophagus 2016; 29:236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leake PA, Cardoso R, Seevaratnam R, et al. A systematic review of the accuracy and indications for diagnostic laparoscopy prior to curative-intent resection of gastric cancer. Gastric Cancer 2012; 15 Suppl 1:S38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abe S, Yoshimura H, Tabara H, et al. Curative resection of gastric cancer: limitation of peritoneal lavage cytology in predicting the outcome. J Surg Oncol 1995; 59:226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bando E, Yonemura Y, Endou Y, et al. Immunohistochemical study of MT-MMP tissue status in gastric carcinoma and correlation with survival analyzed by univariate and multivariate analysis. Oncol Rep 1998; 5:1483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burke EC, Karpeh MS Jr, Conlon KC, Brennan MF. Peritoneal lavage cytology in gastric cancer: an independent predictor of outcome. Ann Surg Oncol 1998; 5:411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leake PA, Cardoso R, Seevaratnam R, et al. A systematic review of the accuracy and utility of peritoneal cytology in patients with gastric cancer. Gastric Cancer 2012; 15 Suppl 1:S27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horie Y, Miura K, Matsui K, et al. Marked elevation of plasma carcinoembryonic antigen and stomach carcinoma. Cancer 1996; 77:1991.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kodama I, Koufuji K, Kawabata S, et al. The clinical efficacy of CA 72-4 as serum marker for gastric cancer in comparison with CA19-9 and CEA. Int Surg 1995; 80:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carpelan-Holmström M, Louhimo J, Stenman UH, et al. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res 2002; 22:2311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lai IR, Lee WJ, Huang MT, Lin HH. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence. Hepatogastroenterology 2002; 49:1157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marrelli D, Pinto E, De Stefano A, et al. Clinical utility of CEA, CA 19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancer. Am J Surg 2001; 181:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mihmanli M, Dilege E, Demir U, et al. The use of tumor markers as predictors of prognosis in gastric cancer. Hepatogastroenterology 2004; 51:1544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marrelli D, Pinto E, De Stefano A, et al. Preoperative positivity of serum tumor markers is a strong predictor of hematogenous recurrence of gastric cancer. J Surg Oncol 2001; 78:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kochi M, Fujii M, Kanamori N, et al. Evaluation of serum CEA and CA19-9 levels as prognostic factors in patients with gastric cancer. Gastric Cancer 2000; 3:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bold RJ, Ota DM, Ajani JA, Mansfield PF. Peritoneal and serum tumor markers predict recurrence and survival of patients with resectable gastric cancer. Gastric Cancer 1999; 2:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ishigami S, Natsugoe S, Hokita S, et al. Clinical importance of preoperative carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer. J Clin Gastroenterol 2001; 32:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim DY, Kim HR, Shim JH, et al. Significance of serum and tissue carcinoembryonic antigen for the prognosis of gastric carcinoma patients. J Surg Oncol 2000; 74:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marrelli D, Roviello F, De Stefano A, et al. Prognostic significance of CEA, CA 19-9 and CA 72-4 preoperative serum levels in gastric carcinoma. Oncology 1999; 57:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakata B, Hirakawa-YS Chung K, Kato Y, et al. Serum CA 125 level as a predictor of peritoneal dissemination in patients with gastric carcinoma. Cancer 1998; 83:2488.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tocchi A, Costa G, Lepre L, et al. The role of serum and gastric juice levels of carcinoembryonic antigen, CA19.9 and CA72.4 in patients with gastric cancer. J Cancer Res Clin Oncol 1998; 124:450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sakamoto J, Nakazato H, Teramukai S, et al. Association between preoperative plasma CEA levels and the prognosis of gastric cancer following curative resection. Tumor Marker Committee, Japanese Foundation for Multidisciplinary Treatment of Cancer, Tokyo, Japan. Surg Oncol 1996; 5:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takahashi Y, Takeuchi T, Sakamoto J, et al. The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study. Gastric Cancer 2003; 6:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duraker N, Celik AN. The prognostic significance of preoperative serum CA 19-9 in patients with resectable gastric carcinoma: comparison with CEA. J Surg Oncol 2001; 76:266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu X, Cheng Y, Sheng W, et al. Clinicopathologic features and prognostic factors in alpha-fetoprotein-producing gastric cancers: analysis of 104 cases. J Surg Oncol 2010; 102:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kono K, Amemiya H, Sekikawa T, et al. Clinicopathologic features of gastric cancers producing alpha-fetoprotein. Dig Surg 2002; 19:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang YC, Nagasue N, Kohno H, et al. Clinicopathologic features and long-term results of alpha-fetoprotein-producing gastric cancer. Am J Gastroenterol 1990; 85:1480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ushiku T, Uozaki H, Shinozaki A, et al. Glypican 3-expressing gastric carcinoma: distinct subgroup unifying hepatoid, clear-cell, and alpha-fetoprotein-producing gastric carcinomas. Cancer Sci 2009; 100:626.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oliveira C, Pinheiro H, Figueiredo J, et al. Familial gastric cancer: genetic susceptibility, pathology, and implications for management. Lancet Oncol 2015; 16:e60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Post RS, Vogelaar IP, Carneiro F, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet 2015; 52:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stjepanovic N, Moreira L, Carneiro F, et al. Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol 2019; 30:1558.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2513 Version 49.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8239772" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Cancer of the stomach. A patient care study by the American College of Surgeons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3548347" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Comparison of pseudoachalasia and achalasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/386813" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The Virchow-Troisier node: a historical note.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3716061" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Umbilical metastasis from prostatic carcinoma--Sister Joseph nodule.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1336701" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Incidence and prognosis of Krukenberg tumour in Northern Ireland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5828299" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Blumer's shelf tumor with primary carcinoma of the lung. A case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7776992" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Gastric carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4270762" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Sign of Leser-Trélat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4868603" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Acanthosis nigricans: a study of 90 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/481196" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Microangiopathic hemolytic anemia and cancer: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6986318" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Association of gastric cancer and nephrotic syndrome. An immunologic study in three patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/834136" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7989904" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Systemic polyarteritis nodosa as the initial manifestation of a gastric adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6383166" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Double-contrast barium meal and upper gastrointestinal endoscopy. A comparative study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2916797" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Detection of early gastric cancer in an aggressive endoscopy unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7054024" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Prospective evaluation of biopsy number in the diagnosis of esophageal and gastric carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7859977" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Endoscopic and histologic diagnosis of submucosal tumors of the gastrointestinal tract using combined strip biopsy and bite biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2028694" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Brushing cytology of the upper gastrointestinal tract. Obsolete or not?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2028694" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Brushing cytology of the upper gastrointestinal tract. Obsolete or not?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2028694" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Brushing cytology of the upper gastrointestinal tract. Obsolete or not?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29393964" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Racial disparities in preoperative chemotherapy use in gastric cancer patients in the United States: Analysis of the National Cancer Data Base, 2006-2014.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26897166" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association staging project.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31197829" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Development and validation of a staging system for gastric adenocarcinoma after neoadjuvant chemotherapy and gastrectomy with D2 lymphadenectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31197829" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Development and validation of a staging system for gastric adenocarcinoma after neoadjuvant chemotherapy and gastrectomy with D2 lymphadenectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35914639" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19789243" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Peritoneal metastasis: detection with 16- or 64-detector row CT in patients undergoing surgery for gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8650600" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Laparoscopic staging for gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10433041" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Pretherapeutic laparoscopic staging in advanced gastric carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19228527" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Endoscopic ultrasound can improve the selection for laparoscopy in patients with localized gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9378384" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Spiral computed tomography and operative staging of gastric carcinoma: a comparison with histopathological staging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3357941" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Gastric adenocarcinoma: CT versus surgical staging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15297943" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Staging and preoperative evaluation of upper gastrointestinal malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1523303" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Gastric tumors: radiologic-pathologic correlation and accuracy of T staging with dynamic CT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9166562" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Hydro-CT in patients with gastric cancer: preoperative radiologic staging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10589566" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Helical hydro-CT for diagnosis and staging of gastric carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20501718" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Diagnostic performance of 64-channel multidetector CT in the evaluation of gastric cancer: differentiation of mucosal cancer (T1a) from submucosal involvement (T1b and T2).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11305564" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Hydro-dynamic CT preoperative staging of gastric cancer: correlation with pathological findings. A prospective study of 107 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10845479" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Comparing MR imaging and CT in the staging of gastric carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12592099" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Prospective comparison of endoscopy, endosonography and computed tomography for staging of tumours of the oesophagus and gastric cardia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11809546" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : A comparison of computerised tomography, laparoscopic ultrasound and endoscopic ultrasound in the preoperative staging of oesophago-gastric carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19530124" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Value of multidetector-row computed tomography in the preoperative T and N staging of gastric carcinoma: a large-scale Chinese study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25914908" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Diagnostic accuracy of endoscopic ultrasonography (EUS) for the preoperative locoregional staging of primary gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11080410" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Endoscopic ultrasonography in the preoperative staging of gastric cancer: accuracy and impact on surgical therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11950802" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : You get what you expect? A critical appraisal of imaging methodology in endosonographic cancer staging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14516555" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Accuracy of FDG-PET in Gastric Cancer. Preliminary Experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10096035" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Systematic review of endoscopic ultrasound in gastro-oesophageal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15114303" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Usefulness of three-dimensional, multidetector row CT (virtual gastroscopy and multiplanar reconstruction) in the evaluation of gastric cancer: a comparison with conventional endoscopy, EUS, and histopathology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17513817" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Imaging in local staging of gastric cancer: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8658217" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Endoscopic ultrasonography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11559651" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : A systematic review of the staging performance of endoscopic ultrasound in gastro-oesophageal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1924784" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Preoperative staging of gastric cancer: comparison of endoscopic US and dynamic CT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7480743" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Lymph-node metastases: efficacy for detection with helical CT in patients with gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10556006" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Experience of endoscopic ultrasound in staging adenocarcinoma of the cardia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16440415" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Usefulness of endoscopic ultrasonography in preoperative TNM staging of gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7859967" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Endoscopic ultrasound-guided fine-needle aspiration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8905352" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Clinical implications of endoscopic ultrasound: the American Endosonography Club Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27447571" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Metastatic spread in patients with gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15856477" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22549558" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31377821" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Staging FDG PET-CT changes management in patients with gastric adenocarcinoma who are eligible for radical treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30643947" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Routinely staging gastric cancer with 18F-FDG PET-CT detects additional metastases and predicts early recurrence and death after surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27115836" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : The value of FDG-PET in the staging of gastric adenocarcinoma: A single institution retrospective review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34705049" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : 18F-Fludeoxyglucose-Positron Emission Tomography/Computed Tomography and Laparoscopy for Staging of Locally Advanced Gastric Cancer: A Multicenter Prospective Dutch Cohort Study (PLASTIC).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16204706" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12732669" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11914891" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Whole-body PET with FDG for the diagnosis of recurrent gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12552348" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16228236" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Assessment of lymph node metastases using 18F-FDG PET in patients with advanced gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16952037" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Usefulness of preoperative FDG-PET for detection of gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2532050" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Laparoscopy, ultrasound and computed tomography in cancer of the oesophagus and gastric cardia: a prospective comparison for detecting intra-abdominal metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16399124" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Selection of patients with gastric adenocarcinoma for laparoscopic staging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25758761" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Accuracy of staging laparoscopy in detecting peritoneal dissemination in patients with gastroesophageal adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21667136" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : A systematic review of the accuracy and indications for diagnostic laparoscopy prior to curative-intent resection of gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7630168" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Curative resection of gastric cancer: limitation of peritoneal lavage cytology in predicting the outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9769392" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Immunohistochemical study of MT-MMP tissue status in gastric carcinoma and correlation with survival analyzed by univariate and multivariate analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9718170" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Peritoneal lavage cytology in gastric cancer: an independent predictor of outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21809111" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : A systematic review of the accuracy and utility of peritoneal cytology in patients with gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8640661" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Marked elevation of plasma carcinoembryonic antigen and stomach carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7657491" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : The clinical efficacy of CA 72-4 as serum marker for gastric cancer in comparison with CA19-9 and CEA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12174919" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12143226" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11248169" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Clinical utility of CEA, CA 19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15362797" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : The use of tumor markers as predictors of prognosis in gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11745820" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Preoperative positivity of serum tumor markers is a strong predictor of hematogenous recurrence of gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11984734" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Evaluation of serum CEA and CA19-9 levels as prognostic factors in patients with gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11957063" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Peritoneal and serum tumor markers predict recurrence and survival of patients with resectable gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11154168" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Clinical importance of preoperative carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10951413" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Significance of serum and tissue carcinoembryonic antigen for the prognosis of gastric carcinoma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10394126" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Prognostic significance of CEA, CA 19-9 and CA 72-4 preoperative serum levels in gastric carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9874453" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Serum CA 125 level as a predictor of peritoneal dissemination in patients with gastric carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9750022" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : The role of serum and gastric juice levels of carcinoembryonic antigen, CA19.9 and CA72.4 in patients with gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8908719" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Association between preoperative plasma CEA levels and the prognosis of gastric cancer following curative resection. Tumor Marker Committee, Japanese Foundation for Multidisciplinary Treatment of Cancer, Tokyo, Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14520526" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11320518" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : The prognostic significance of preoperative serum CA 19-9 in patients with resectable gastric carcinoma: comparison with CEA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20740583" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Clinicopathologic features and prognostic factors in alpha-fetoprotein-producing gastric cancers: analysis of 104 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12435906" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Clinicopathologic features of gastric cancers producing alpha-fetoprotein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1700600" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Clinicopathologic features and long-term results of alpha-fetoprotein-producing gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19243386" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Glypican 3-expressing gastric carcinoma: distinct subgroup unifying hepatoid, clear-cell, and alpha-fetoprotein-producing gastric carcinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25638682" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Familial gastric cancer: genetic susceptibility, pathology, and implications for management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25979631" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31378807" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
